69 related articles for article (PubMed ID: 37183966)
21. Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies.
Ip BBK; Wong ATC; Law JHY; Au CH; Ma SY; Chim JCS; Liang RHS; Leung AYH; Wan TSK; Ma ESK
Sci Rep; 2024 Mar; 14(1):6400. PubMed ID: 38493200
[TBL] [Abstract][Full Text] [Related]
22. Vidjil add-on for MRD quantification of samples processed using the EuroClonality-NGS protocol.
Giusti GNN; Ribeiro AV; Jotta PY; Thonier F; Yunes JA; Meidanis J
EJHaem; 2023 Aug; 4(3):770-774. PubMed ID: 37601854
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease in Philadelphia-positive acute lymphoblastic leukemia: Maximizing the clinical yield of testing.
Saliba AN; Foà R
Am J Hematol; 2023 Aug; 98(8):1168-1170. PubMed ID: 37314420
[No Abstract] [Full Text] [Related]
24. Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase.
Cardinali D; Beldinanzi M; Ansuinelli M; Elia L; Della Starza I; Bellomarino V; Matarazzo M; Di Trani M; Cola M; Salutari P; Cedrone M; Bassan R; De Gobbi M; Della Porta MG; De Simone M; Alati C; Fracchiolla NS; Lunghi M; Intermesoli T; Cardinali V; Mulè A; Guarini A; Foà R; Chiaretti S
Leuk Lymphoma; 2023; 64(11):1884-1887. PubMed ID: 37452789
[No Abstract] [Full Text] [Related]
25. Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia.
Ramos Elbal E; Fuster JL; Campillo JA; Galera AM; Cortés MB; Llinares ME; Jiménez I; Plaza M; Martínez Banaclocha H; Galián JA; Blanquer Blanquer M; Martínez Sánchez MV; Muro M; Minguela A
Clin Transl Oncol; 2024 Jan; 26(1):278-287. PubMed ID: 37368200
[TBL] [Abstract][Full Text] [Related]
26. Hematological, clinical, immunophenotypic characterization, and treatment outcomes of prognostically significant genetic subtypes of B-lineage acute lymphoblastic leukemia: A report of 1021 patients from India.
Gupta DG; Varma N; Sharma P; Truica MI; Abdulkadir SA; Singh P; Singh Sachdeva MU; Naseem S; Siddiqui MR; Bose P; Binota J; Malhotra P; Khadwal A; Trehan A; Varma S
Cancer; 2023 Nov; 129(21):3390-3404. PubMed ID: 37498973
[TBL] [Abstract][Full Text] [Related]
27. Impact of MRD on clinical outcomes of unrelated hematopoietic stem cell transplantation in patients with Ph
Hirabayashi S; Kondo T; Nishiwaki S; Mizuta S; Doki N; Fukuda T; Uchida N; Ozawa Y; Kanda Y; Imanaka R; Takahashi S; Ishikawa J; Yano S; Nakamae H; Eto T; Kimura T; Tanaka J; Ichinohe T; Atsuta Y; Kako S
Am J Hematol; 2023 Oct; 98(10):1606-1618. PubMed ID: 37493218
[TBL] [Abstract][Full Text] [Related]
28. Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation.
Liang EC; Dekker SE; Sabile JMG; Torelli S; Zhang A; Miller K; Shiraz P; Hayes-Lattin B; Leonard JT; Muffly L
Blood Adv; 2023 Jul; 7(14):3395-3402. PubMed ID: 37196642
[TBL] [Abstract][Full Text] [Related]
29. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial.
Schubert ML; Schmitt A; Hückelhoven-Krauss A; Neuber B; Kunz A; Waldhoff P; Vonficht D; Yousefian S; Jopp-Saile L; Wang L; Korell F; Keib A; Michels B; Haas D; Sauer T; Derigs P; Kulozik A; Kunz J; Pavel P; Laier S; Wuchter P; Schmier J; Bug G; Lang F; Gökbuget N; Casper J; Görner M; Finke J; Neubauer A; Ringhoffer M; Wolleschak D; Brüggemann M; Haas S; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
J Hematol Oncol; 2023 Jul; 16(1):79. PubMed ID: 37481608
[TBL] [Abstract][Full Text] [Related]
30. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
Short NJ; Muftuoglu M; Ong F; Nasr L; Macaron W; Montalban-Bravo G; Alvarado Y; Basyal M; Daver N; Dinardo CD; Borthakur G; Jain N; Ohanian M; Jabbour E; Issa GC; Qiao W; Huang X; Kanagal-Shamanna R; Patel KP; Bose P; Ravandi F; Delumpa R; Abramova R; Garcia-Manero G; Andreeff M; Cortes J; Kantarjian H
J Hematol Oncol; 2023 Jul; 16(1):73. PubMed ID: 37422688
[TBL] [Abstract][Full Text] [Related]
31. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P
Front Immunol; 2023; 14():1191382. PubMed ID: 37469510
[TBL] [Abstract][Full Text] [Related]
32. The recombinome of IKZF1 deletions in B-cell precursor ALL.
Lopes BA; Meyer C; Bouzada H; Külp M; Maciel ALT; Larghero P; Barbosa TC; Poubel CP; Barbieri C; Venn NC; Pozza LD; Barbaric D; Palmi C; Fazio G; Saitta C; Aguiar TF; Lins MM; Ikoma-Colturato MRV; Schramm M; Chapchap E; Cazzaniga G; Sutton R; Marschalek R; Emerenciano M
Leukemia; 2023 Aug; 37(8):1727-1731. PubMed ID: 37386080
[No Abstract] [Full Text] [Related]
33. PersonALL: a genetic scoring guide for personalized risk assessment in pediatric B-cell precursor acute lymphoblastic leukemia.
Bedics G; Egyed B; Kotmayer L; Benard-Slagter A; de Groot K; Bekő A; Hegyi LL; Bátai B; Krizsán S; Kriván G; Erdélyi DJ; Müller J; Haltrich I; Kajtár B; Pajor L; Vojcek Á; Ottóffy G; Ujfalusi A; Szegedi I; Tiszlavicz LG; Bartyik K; Csanádi K; Péter G; Simon R; Hauser P; Kelemen Á; Sebestyén E; Jakab Z; Matolcsy A; Kiss C; Kovács G; Savola S; Bödör C; Alpár D
Br J Cancer; 2023 Aug; 129(3):455-465. PubMed ID: 37340093
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6::ABL2 fusion in T-ALL.
Lahera A; Vela-Martín L; López-Nieva P; Salgado RN; Rodríguez-Perales S; Torres-Ruiz R; López-Lorenzo JL; Cornago J; Llamas P; Fernández-Navarro P; Sánchez-Domínguez R; Segovia JC; Sastre I; Cobos-Fernández MÁ; Menéndez P; Santos J; Fernández-Piqueras J; Villa-Morales M
Br J Haematol; 2023 Aug; 202(3):693-698. PubMed ID: 37264982
[No Abstract] [Full Text] [Related]
35. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in
Senapati J; Jabbour E; Konopleva M; Short NJ; Tang G; Daver N; Kebriaei P; Kadia T; Pemmaraju N; Takahashi K; DiNardo C; Sasaki K; Borthakur G; Thakral B; Kanagal-Shamanna R; Patel K; Ravandi F; Roberts K; Mullighan C; Kantarjian H; Jain N
JCO Precis Oncol; 2023 May; 7():e2200707. PubMed ID: 37196217
[TBL] [Abstract][Full Text] [Related]
36. How to Manage Philadelphia-Positive Acute Lymphoblastic Leukemia in Resource-Constrained Settings.
Silva W; Rego E
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136329
[TBL] [Abstract][Full Text] [Related]
37. Leveraging health care technology to improve health outcomes and reduce outcome disparities in AYA leukemia.
Molina JC; Rotz S
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):573-580. PubMed ID: 38066875
[TBL] [Abstract][Full Text] [Related]
38. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Short NJ; Jabbour E; Macaron W; Ravandi F; Jain N; Kanagal-Shamanna R; Patel KP; Loghavi S; Haddad FG; Yilmaz M; Issa GC; Kebriaei P; Kornblau SM; Pelletier S; Flores W; Matthews J; Garris R; Kantarjian H
Am J Hematol; 2023 Aug; 98(8):1196-1203. PubMed ID: 37183966
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
40. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Haddad FG; Jabbour E; Short NJ; Jain N; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):271-276. PubMed ID: 38185587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
